Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18006311rdf:typepubmed:Citationlld:pubmed
pubmed-article:18006311lifeskim:mentionsumls-concept:C1334126lld:lifeskim
pubmed-article:18006311lifeskim:mentionsumls-concept:C1334125lld:lifeskim
pubmed-article:18006311lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:18006311pubmed:issue1lld:pubmed
pubmed-article:18006311pubmed:dateCreated2008-1-9lld:pubmed
pubmed-article:18006311pubmed:abstractTextA series of novel and potent 3,4-diamino-2,5-thiadiazole-1-oxides were prepared and found to show excellent binding affinities for CXCR2 and CXCR1 receptors and excellent inhibitory activity of Gro-alpha and IL-8 mediated in vitro hPMN MPO release of CXCR2 and CXCR1 expressing cell lines. On the other hand, a closely related 3,4-diamino-2,5-thiadiazole-dioxide did not show functional activity despite its excellent binding affinities for CXCR2 and CXCR1 in membrane binding assays. A detailed SAR has been discussed in these two closely related structures.lld:pubmed
pubmed-article:18006311pubmed:languageenglld:pubmed
pubmed-article:18006311pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:citationSubsetIMlld:pubmed
pubmed-article:18006311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18006311pubmed:statusMEDLINElld:pubmed
pubmed-article:18006311pubmed:monthJanlld:pubmed
pubmed-article:18006311pubmed:issn1464-3405lld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:JakwayJamesJlld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:FanXuedongXlld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:HipkinR...lld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:QiuHongchenHlld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:FossettaJames...lld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:YuYounongYlld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:BaldwinJohn...lld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:FineJayJlld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:ZhengJunyingJlld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:MerrittJ...lld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:ChaoJianhuaJlld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:BijuPurakkatt...lld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:RindgenDianeDlld:pubmed
pubmed-article:18006311pubmed:authorpubmed-author:TaverasArthur...lld:pubmed
pubmed-article:18006311pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18006311pubmed:day1lld:pubmed
pubmed-article:18006311pubmed:volume18lld:pubmed
pubmed-article:18006311pubmed:ownerNLMlld:pubmed
pubmed-article:18006311pubmed:authorsCompleteYlld:pubmed
pubmed-article:18006311pubmed:pagination228-31lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:meshHeadingpubmed-meshheading:18006311...lld:pubmed
pubmed-article:18006311pubmed:year2008lld:pubmed
pubmed-article:18006311pubmed:articleTitle3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.lld:pubmed
pubmed-article:18006311pubmed:affiliationSchering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. purakkattle.biju@spcorp.comlld:pubmed
pubmed-article:18006311pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:18006311lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18006311lld:pubmed